The National Lung Matrix Trial of personalized therapy in lung cancer.

Bayes Theorem Carcinoma, Non-Small-Cell Lung / etiology Clinical Protocols Clinical Trials as Topic Cohort Studies Genetic Markers Genotype High-Throughput Nucleotide Sequencing Humans Lung Neoplasms / etiology Molecular Targeted Therapy Oncogenes / genetics Patient Selection Precision Medicine Smoke / adverse effects Smoking / genetics Triage

Journal

Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462

Informations de publication

Date de publication:
07 2020
Historique:
received: 28 01 2020
accepted: 08 06 2020
pubmed: 17 7 2020
medline: 21 10 2020
entrez: 17 7 2020
Statut: ppublish

Résumé

The majority of targeted therapies for non-small-cell lung cancer (NSCLC) are directed against oncogenic drivers that are more prevalent in patients with light exposure to tobacco smoke

Identifiants

DOI: 10.1038/s41586-020-2481-8 PMID: 32669708 PMC: PMC7116732
pubmed: 32669708
doi: 10.1038/s41586-020-2481-8
pii: 10.1038/s41586-020-2481-8
pmc: PMC7116732
mid: EMS114936
doi:

Substances chimiques

Genetic Markers 0
Smoke 0

Types de publication

Clinical Trial, Phase II Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

807-812

Subventions

Organisme : Medical Research Council
ID : FC001169
Pays : United Kingdom
Organisme : Cancer Research UK
ID : FC001169
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 12820
Pays : United Kingdom
Organisme : Cancer Research UK
ID : A22209
Pays : United Kingdom
Organisme : Wellcome Trust
ID : FC001169
Pays : United Kingdom
Organisme : Cancer Research UK
ID : A19363
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : ErratumIn

Références

Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129–2139 (2004).
doi: 10.1056/NEJMoa040938
Bergethon, K. et al. ROS1 rearrangements define a unique molecular class of lung cancers. J. Clin. Oncol. 30, 863–870 (2012).
doi: 10.1200/JCO.2011.35.6345
Kwak, E. L. et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363, 1693–1703 (2010).
doi: 10.1056/NEJMoa1006448
Carr, T. H. et al. Defining actionable mutations for oncology therapeutic development. Nat. Rev. Cancer 16, 319–329 (2016).
doi: 10.1038/nrc.2016.35
Berry, S. M., Carlin, B. P., Lee, J. J. & Muller, P. Bayesian Adaptive Methods for Clinical Trials (CRC, 2010).
Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228–247 (2009).
doi: 10.1016/j.ejca.2008.10.026
The Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511, 543–550 (2014).
doi: 10.1038/nature13385
The Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 489, 519–525 (2012).
doi: 10.1038/nature11404
Koselugo (selumetinib) approved in US for paediatric patients with neurofibromatosis type 1 plexiform neurofibromas. https://www.astrazeneca.com/media-centre/press-releases/2020/koselugo-selumetinib-approved-in-us-for-paediatric-patients-with-neurofibromatosis-type-1-plexiform-neurofibromas.html (AstraZeneca, 2020).
Schmid, P. et al. Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: the PAKT trial. J. Clin. Oncol. 38, 423–433 (2020).
doi: 10.1200/JCO.19.00368
Jamal-Hanjani, M. et al. Tracking the evolution of non-small-cell lung cancer. N. Engl. J. Med. 376, 2109–2121 (2017).
doi: 10.1056/NEJMoa1616288
de Bruin, E. C. et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 346, 251–256 (2014).
doi: 10.1126/science.1253462
Kim, I. A., Lee, J. S., Kim, H. J., Kim, W. S. & Lee, K. Y. Cumulative smoking dose affects the clinical outcomes of EGFR-mutated lung adenocarcinoma patients treated with EGFR-TKIs: a retrospective study. BMC Cancer 18, 768 (2018).
doi: 10.1186/s12885-018-4691-0
Offin, M. et al. Tumor mutation burden and efficacy of EGFR-tyrosine kinase inhibitors in patients with EGFR-mutant lung cancers. Clin. Cancer Res. 25, 1063–1069 (2019).
doi: 10.1158/1078-0432.CCR-18-1102
McFadden, D. G. et al. Mutational landscape of EGFR-, MYC-, and Kras-driven genetically engineered mouse models of lung adenocarcinoma. Proc. Natl Acad. Sci. USA 113, E6409–E6417 (2016).
doi: 10.1073/pnas.1613601113
Westcott, P. M. et al. The mutational landscapes of genetic and chemical models of Kras-driven lung cancer. Nature 517, 489–492 (2015).
doi: 10.1038/nature13898
Liao, R. G. et al. Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. Cancer Res. 73, 5195–5205 (2013).
doi: 10.1158/0008-5472.CAN-12-3950
Castiglione, R. et al. Comparison of the genomic background of MET-altered carcinomas of the lung: biological differences and analogies. Mod. Pathol. 32, 627–638 (2019).
doi: 10.1038/s41379-018-0182-8
Gautschi, O. et al. Targeting RET in patients with RET-rearranged lung cancers: results from the global, multicenter RET registry. J. Clin. Oncol. 35, 1403–1410 (2017).
doi: 10.1200/JCO.2016.70.9352
Subbiah, V. et al. Precision targeted therapy with BLU-667 for RET-driven cancers. Cancer Discov. 8, 836–849 (2018).
doi: 10.1158/2159-8290.CD-18-0338
Morgan, P. et al. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving phase II survival. Drug Discov. Today 17, 419–424 (2012).
doi: 10.1016/j.drudis.2011.12.020
Basu, B. et al. First-in-human pharmacokinetic and pharmacodynamic study of the dual m-TORC 1/2 inhibitor AZD2014. Clin. Cancer Res. 21, 3412–3419 (2015).
doi: 10.1158/1078-0432.CCR-14-2422
Rothwell, D. G. et al. Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study. Nat. Med. 25, 738–743 (2019).
doi: 10.1038/s41591-019-0380-z
Pengelly, R. J. et al. A SNP profiling panel for sample tracking in whole-exome sequencing studies. Genome Med. 5, 89 (2013).
doi: 10.1186/gm492
Kim, S. et al. Strelka2: fast and accurate calling of germline and somatic variants. Nat. Methods 15, 591–594 (2018).
doi: 10.1038/s41592-018-0051-x
Chen, X. et al. Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications. Bioinformatics 32, 1220–1222 (2016).
Thall, P. F., Wooten, L. H. & Tannir, N. M. Monitoring event times in early phase clinical trials: some practical issues. Clin. Trials 2, 467–478 (2005).
doi: 10.1191/1740774505cn121oa
Van Loo, P. et al. Allele-specific copy number analysis of tumors. Proc. Natl Acad. Sci. USA 107, 16910–16915 (2010).
doi: 10.1073/pnas.1009843107
Bailey, M. H. et al. Comprehensive characterization of cancer driver genes and mutations. Cell 173, 371–385.e18 (2018).
doi: 10.1016/j.cell.2018.02.060
Wang, K. et al. PennCNV: an integrated hidden Markov model designed for high-resolution copy number variation detection in whole-genome SNP genotyping data. Genome Res. 17, 1665–1674 (2007).
Cheng, J. et al. Single-cell copy number variation detection. Genome Biol. 12, R80 (2011).
Abbosh, C. et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature 545, 446–451 (2017).

Auteurs

Gary Middleton (G)

Institute of Immunology & Immunotherapy, University of Birmingham, Birmingham, UK. g.middleton@bham.ac.uk.
University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. g.middleton@bham.ac.uk.
ORCID: 0000-0001-5695-3474

Peter Fletcher (P)

Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK.

Sanjay Popat (S)

The Royal Marsden Hospital, London, UK.
ORCID: 0000-0003-2087-4963

Joshua Savage (J)

Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK.
ORCID: 0000-0003-0599-0245

Yvonne Summers (Y)

The Christie, Manchester, UK.

Alastair Greystoke (A)

Newcastle University, Newcastle, UK.

David Gilligan (D)

Addenbrooke's Hospital, Cambridge, UK.

Judith Cave (J)

Southampton University Hospitals NHS Trust, Southampton, UK.

Noelle O'Rourke (N)

Beatson West of Scotland Cancer Centre, Glasgow, UK.

Alison Brewster (A)

Velindre Cancer Centre, Cardiff, UK.

Elizabeth Toy (E)

Royal Devon and Exeter Foundation NHS Trust, Exeter, UK.

James Spicer (J)

King's College London, Guy's Hospital, London, UK.

Pooja Jain (P)

St James's University Hospital, Leeds, UK.

Adam Dangoor (A)

Bristol Haematology and Oncology Centre, Bristol, UK.
ORCID: 0000-0003-3533-6842

Melanie Mackean (M)

Western General Hospital, Edinburgh, UK.

Martin Forster (M)

University College Hospital, London, UK.

Amanda Farley (A)

Institute of Applied Health Research, University of Birmingham, Birmingham, UK.

Dee Wherton (D)

Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK.

Manita Mehmi (M)

Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK.
ORCID: 0000-0001-8220-9331

Rowena Sharpe (R)

Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK.

Tara C Mills (TC)

Cancer Research UK, London, UK.

Maria Antonietta Cerone (MA)

Cancer Research UK, London, UK.

Timothy A Yap (TA)

The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
ORCID: 0000-0002-2154-3309

Thomas B K Watkins (TBK)

The Francis Crick Institute, London, UK.

Emilia Lim (E)

The Francis Crick Institute, London, UK.

Charles Swanton (C)

The Francis Crick Institute, London, UK.
Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, University College London, London, UK.
ORCID: 0000-0002-4299-3018

Lucinda Billingham (L)

Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK.

Articles similaires

Comprehensive comparative analysis and development of molecular markers for Lasianthus species based on complete chloroplast genome sequences.

Yue Zhang, Meifang Song, Deying Tang et al.
1.00
Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH

questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Probabilité › Théorème de Bayes › The National Lung Matrix Trial of personalized...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Tumeurs de l'appareil respiratoire › Tumeurs du poumon › Tumeurs des bronches › Carcinome bronchogénique › Carcinome pulmonaire non à petites cellules › The National Lung Matrix Trial of personalized...
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Protocoles cliniques › The National Lung Matrix Trial of personalized...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études cliniques comme sujet › Essais cliniques comme sujet › The National Lung Matrix Trial of personalized...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › The National Lung Matrix Trial of personalized...
questionsmedicales.fr › Phénomènes génétiques › Phénotype › Marqueurs génétiques › The National Lung Matrix Trial of personalized...
questionsmedicales.fr › Phénomènes génétiques › Génotype › The National Lung Matrix Trial of personalized...
questionsmedicales.fr › Techniques d'investigation › Techniques génétiques › Analyse de séquence › Séquençage nucléotidique à haut débit › The National Lung Matrix Trial of personalized...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › The National Lung Matrix Trial of personalized...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Tumeurs de l'appareil respiratoire › Tumeurs du poumon › The National Lung Matrix Trial of personalized...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Thérapie moléculaire ciblée › The National Lung Matrix Trial of personalized...
questionsmedicales.fr › Phénomènes génétiques › Structures génétiques › Génome › Composants de génome › Gènes › Gènes tumoraux › Oncogènes › The National Lung Matrix Trial of personalized...
questionsmedicales.fr › Administration des services de santé › Gestion des soins aux patients › Sélection de patients › The National Lung Matrix Trial of personalized...
questionsmedicales.fr › Professions de santé › Médecine › Médecine clinique › Médecine de précision › The National Lung Matrix Trial of personalized...
questionsmedicales.fr › Mélanges complexes › Matière particulaire › Fumée › The National Lung Matrix Trial of personalized...
questionsmedicales.fr › Comportement et mécanismes comportementaux › Comportement › Fumer › The National Lung Matrix Trial of personalized...
questionsmedicales.fr › Établissements, main d'oeuvre et services de soins de santé › Services de santé › Services des urgences médicales › Triage › The National Lung Matrix Trial of personalized...